<DOC>
	<DOCNO>NCT00146146</DOCNO>
	<brief_summary>The purpose study : - determine role testosterone versus dihydrotestosterone respect follow physiological function : bone metabolism , body composition , insulin resistance lipid profile - determine role testosterone dihydrotestosterone versus estradiol respect follow physiological function : bone metabolism , body composition , insulin resistance lipid profile</brief_summary>
	<brief_title>Testosterone Its Metabolites GID</brief_title>
	<detailed_description>BACKGROUND GID psychic disorder otherwise normal person feel like he/she member opposite sex she/he belong biologically . These patient require hormonal treatment suppress somatic characteristic sex develop somatic characteristic sex . After psychotherapy period hormonal treatment , undergo surgical sex reassignment , case FtM subject , consist hystero-adnexectomy , reductive mastoplasty possibly penile reconstruction . Thereafter , entire life , must treat testosterone ( T ) maintain androgen-dependent physiological function . RATIONALE After sex-reassignment surgery , FtM subject must treat T entire life order maintain androgen-estrogen dependent physiological function . These subject represent interest model study effect testosterone metabolites different physiological function . As , information androgen receptor differ male female . Therefore , induction androgen effect FtM subject consider similar hypogonadal men FtM subject serve model hypogonadal male . Therefore , aim trial evaluate effect selective steroid replacement different physiological function . In particular study evaluate relative role testosterone , DHT estradiol different physiological function . For purpose , administer testosterone undecanoate alone ( Group A ) combination letrozole , aromatase inhibitor ( Group B ) . A third group FtM subject treat TU plus dutasteride ( Group C ) . In view development selective androgen receptor modulators , understand relative role steroid different physiological function provide useful information future therapeutic indication . The information collect study greatly help optimize long-term treatment FtM subject . In particular , study , test follow question : - role testosterone vs. DHT physiological function evaluate study i.e . bone metabolism , body composition , insulin resistance lipid profile ( Group B vs. Group C ) - role testosterone DHT v estradiol physiological function evaluate study i.e . bone metabolism , body composition , insulin resistance lipid profile ( Group C vs. Group A ) DESIGN For purpose , study treat FtM castrate , subject 54 week : - testosterone undecanoate 1000 mg 6-12 week ( injection week 0 , 6 , 18 , 30 , 42 54 ) ( n=5 ) ( Group A ) - testosterone undecanoate 1000 mg 6-12 week ( injection week 0 , 6 , 18 , 30 , 42 54 ) mg/day plus letrozole 2.5 mg/day ( n=5 ) ( Group B ) - testosterone undecanoate 1000 mg 6-12 week ( injection week 0 , 6 , 18 , 30 , 42 54 ) plus dutasteride 0.5 mg/day ( n=5 ) ( Group C ) Overall study design plan-description Prospective , phase III , randomize study design use . The study consist control phase last 3 week 54-week treatment period . Control phase : ( last 3 week : In period , subject provide three fasting ( least 10 hour ) blood sample one urine sample . Subjects undergo 2 visit ensure fulfillment inclusion criterion , absence exclusion criterion , determine state health inform purpose study . During two visit , undergo : - blood drawing measurement : LH , FSH , estradiol , testosterone DHEAS , total cholesterol , HDL cholesterol , triglyceride , insulin , glucose , leptin , adiponectin , uric acid , urea , creatinine , Na , K , Ca , P , Mg , Cl , total protein , bone alkaline phosphate , PTH , osteocalcin , crosslaps , 25 ( OH ) vit D , H RANKL , osteoprotegerin . - anthropometry : weight , measure - DEXA bone mass determination body composition - physical examination - sexual behavioral questionnaire - pain questionnaire Treatment phase All injection administer investigator co-investigators entire study . Fasting ( 10 hour ) blood sample take ( immediately give injection ) every time subject come injection ( week 0 , 6 , 18 , 30 42 ) end treatment phase . On occasion , physical examination include weight , blood pressure pulse rate check perform . Volunteers ask complete sexual behavioral questionnaire pain questionnaire visit . At week 6 , 18 , 30 42 follow test perform : - blood drawing measurement : LH , FSH , estradiol , testosterone , DHT , total cholesterol , HDL cholesterol , triglyceride , insulin , glucose , leptin , adiponectin , uric acid , urea , creatinine , Na , K , Ca , P , Mg , Cl , total protein . - anthropometry : weight , measure - physical examination - sexual behavioral questionnaire - pain questionnaire At week 54 follow test perform : - blood drawing measurement : LH , FSH , estradiol , testosterone , DHT , DHEAS , total cholesterol , HDL cholesterol , triglyceride , insulin , glucose , leptin , adiponectin , uric acid , urea , creatinine , Na , K , Ca , P , Mg , Cl , total protein , bone alkaline phosphate , PTH , osteocalcin , crosslaps , 25 ( OH ) vit D , H RANKL , osteoprotegerin . - anthropometry : weight , measure - DEXA bone mass determination body composition - physical examination - sexual behavioral questionnaire - pain questionnaire Measurements : Blood sample ( 10 hour last food intake ) . Blood collection carry venipuncture . After rest room temperature 30 min , sample centrifuge 3000 rpm 10 min . Serum sample ( 10 ml ) blood sample store -20°C analysis . Physical examination : They include inspection external genitalia ( clitorides ) visit detect appearance acne gynecomastia . Sexual function behavior questionnaire : In sexual behavior questionnaire subject judge sexual activity behavior period visit . The subject possibility make additional comment important event disturbance . SELECTION OF STUDY POPULATION : Healthy female FtM subject , undergone SR surgery ( hystero-adnexectomy ) recruit participate study . Healthy female subject 18 45 year age enrol study accord Inclusion/Exclusion Criteria list . They inform nature , aim objective study require give write consent participate study . The presence inclusion criterion absence exclusion criterion document Case Report Forms ( CRF ) .</detailed_description>
	<mesh_term>Transsexualism</mesh_term>
	<mesh_term>Dutasteride</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Healthy biological female , 18 45 year age : SR surgery perform Body Mass Index ( BMI ) 20 29 kg/m² ; ( body weight kilogram divide body height meter square ) Clinical examination without pathological finding relevant study Clinicochemical laboratory value suggest illness Written Consent Form sign High probability good compliance termination study Subjects enrol study one follow criterion apply : Participation another clinical trial within 30 day precede first administration Simultaneous participation another clinical trial Subjects institutionalize imprisoned order court Subject compete sport use IOC drug monitor Serious organic psychic disease suspect history and/or clinical examination Diseases ( especially tumor ) might represent actual contraindication testosterone Past present history thrombotic embolic diseases Hypertension require therapy ( BP 140/90 mmHg ) Diabetes mellitus require therapy Acute chronic hepatic disease Manifest renal disease renal dysfunction Severe internal disease well use medication treat Biochemical and/or hematological laboratory value beyond normal range unless Investigator confirm deviation clinical relevance Any indication chronic use drug , alcohol , opiates recreational drug Use drug know affect biotransformation testosterone and/or progestin , e.g . chlorcycline , phenobarbital , phenylbutazone , aminophenazone within 30 day precede first administration test medication study Use oral anticoagulatory drug within 30 day precede first administration test medication study Any oral transdermal hormone medication within 12 week precede first administration study Probability poor compliance termination study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>transsexualism</keyword>
	<keyword>testosterone</keyword>
	<keyword>dihydrotestosterone</keyword>
	<keyword>estradiol</keyword>
</DOC>